GLP-2 is a novel dual incretin mimetic peptide that activates both GLP-2 (glucagon-like peptide-2) and GIP (glucose-dependent insulinotropic polypeptide) receptors. By stimulating these pathways, GLP-2 enhances insulin secretion, reduces glucagon levels, slows gastric emptying, suppresses appetite, and increases satiety. It has been shown in clinical trials to significantly reduce body weight and improve glycemic control. GLP-2 is much like the FDA-approved peptide for type 2 diabetes (Mounjaro®) and chronic weight management (Zepbound™).
How The Peptide Is Used in Research Settings
- Studied for weight management and obesity through appetite suppression and increased energy expenditure.
- Investigated in type 2 diabetes for improved insulin sensitivity and glycemic control.
- Explored for reducing cardiovascular risk factors such as inflammation and dyslipidemia.
- Examined in liver health research for potential benefits in NAFLD and NASH models.
Proposed Uses (Research Areas)
- Obesity and weight management studies.
- Type 2 diabetes and insulin resistance models.
- Cardiovascular health and metabolic syndrome research.
- Liver disease studies (NAFLD/NASH).
How It Is Dosed in Research Settings
- Injectable (Subcutaneous): Studied and approved dosing begins at 2.5 mg once weekly, titrating up to 5 mg, 10 mg, or 15 mg weekly depending on response and tolerance.
- Titration schedule: Typically escalated every 4 weeks to minimize gastrointestinal side effects.
- Cycle length: Clinical research spans 40–72 weeks or longer to evaluate sustained effects on weight loss, glycemic control, and cardiometabolic outcomes.
- Handling: Supplied as pre-formulated injection pens; requires refrigeration for stability.
Important Considerations
- Regulatory status: FDA-approved for type 2 diabetes and obesity; all other applications remain experimental.
- Evidence base: Phase 3 SURPASS and SURMOUNT clinical trials demonstrate substantial weight loss (up to 20%+ of body weight) and improved metabolic outcomes compared to GLP-1.
- Safety: Reported side effects include nausea, vomiting, diarrhea, constipation, and reduced appetite. Rare but serious risks include pancreatitis, gallbladder disease, and potential thyroid C-cell tumors (as seen in rodent models).
Disclaimer
This material is provided for educational purposes only and summarizes published research on GLP-2.
It is not medical advice. Except for its narrow FDA-approved uses, GLP-2 is experimental and should not be viewed as a therapy for medical use.
This peptide is for research use only.